表紙
市場調查報告書

心房纖維顫動:開發中產品分析

Atrial Fibrillation - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232800
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
心房纖維顫動:開發中產品分析 Atrial Fibrillation - Pipeline Review, H2 2019
出版日期: 2019年11月29日內容資訊: 英文 120 Pages
簡介

所謂心房纖維顫動是指心跳數不規則(或是突然變快)的疾病,會成為人體內部血流停滯的原因。主要症狀有血壓降低及無力感、輕微的頭痛、意識不清、胸痛等。致病因素有年齡及心臟病、高血壓、家族病史、飲酒等。藥物治療、外科手術等是主要的治療法。

本報告提供治療全球各國的心房纖維顫動所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

心房纖維顫動概要

治療藥的開發

  • 心房纖維顫動開發中產品:概要
  • 心房纖維顫動開發中產品:比較分析

各企業開發中的心房纖維顫動治療藥

大學/研究機關研究中的心房纖維顫動治療藥

心房纖維顫動治療藥:開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

心房纖維顫動治療藥:開發中的產品一覽(各企業)

心房纖維顫動治療藥:研究中的產品一覽(各大學/研究機關)

心房纖維顫動開發治療藥的企業

  • ARCA biopharma, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Cardiome Pharma Corp.
  • 第一三共
  • Dong-A Socio Holdings Co. Ltd.
  • Gilead Sciences, Inc.
  • Laboratoires Pierre Fabre SA
  • 日產化學工業
  • OMEICOS Therapeutics GmbH
  • 大塚集團
  • Xention Limited

心房纖維顫動:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

心房纖維顫動治療藥:開發暫停的產品

心房纖維顫動治療藥:開發中止的產品

心房纖維顫動相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11862IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2019, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 4, 10, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Atrial Fibrillation - Overview
  • Atrial Fibrillation - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Atrial Fibrillation - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Atrial Fibrillation - Companies Involved in Therapeutics Development
  • Acesion Pharma Aps
  • Allergan Plc
  • Allosteros Therapeutics Inc
  • AnaBios Corp
  • ARCA biopharma Inc
  • Armaron Bio Pty Ltd
  • Boston Pharmaceuticals Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Correvio Pharma Corp
  • Espero BioPharma Inc
  • G3 Pharmaceuticals Inc
  • Gilead Sciences Inc
  • HUYA Bioscience International LLC
  • InCarda Therapeutics Inc
  • Merck & Co Inc
  • Merz Pharma GmbH & Co KgaA
  • Milestone Pharmaceuticals Inc
  • Nissan Chemical Corp
  • OMEICOS Therapeutics GmbH
  • Rhythm Therapeutics Inc
  • Rithim Biologics Inc
  • The Geneva Biotech Center SA
  • Toa Eiyo Ltd
  • Verseon Corp
  • Vivasc Therapeutics Inc
  • Atrial Fibrillation - Drug Profiles
  • amiodarone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AP-30663 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AS-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BOS-1728515 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bucindolol hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • budiodarone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CKD-825 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • etripamil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • flecainide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GBCA-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Atrial Fibrillation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Post-Operative Atrial Fibrillation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-967 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HBI-3000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • incobotulinumtoxin A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-1832 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NIP-151 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NP-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NTC-801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OMT-28 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • onabotulinumtoxinA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Atrial Fibrillation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TY-55348 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TY-55458 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VE-1902 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vernakalant hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Atrial Fibrillation - Dormant Projects
  • Atrial Fibrillation - Discontinued Products
  • Atrial Fibrillation - Product Development Milestones
  • Featured News & Press Releases
  • Nov 18, 2019: Correvio announces presentation of new Brinavess spectrum data at the American Heart Association 2019 Annual Meeting
  • Nov 04, 2019: Correvio announces FDA advisory committee meeting to review Brinavess for recent onset Atrial Fibrillation
  • Aug 12, 2019: Correvio announces Brinavess spectrum data to be presented at the European Society of Cardiology 2019 Congress
  • Jul 25, 2019: U.S. FDA accepts Correvio's resubmitted New Drug Application for Brinavess (vernakalant)
  • Jun 24, 2019: Correvio resubmits Brinavess (Vernakalant) new drug application to U.S. FDA for the treatment of patients with recent onset atrial fibrillation
  • Apr 30, 2019: Omeicos doses first patient in Phase II trial of OMT-28 programme
  • Apr 03, 2019: InCarda Therapeutics appoints Daniel G. Welch as Executive Chairman of Board of Directors
  • Mar 20, 2019: Correvio announces presentation Of Brinavess data At The American College Of Cardiology 2019 Annual Meeting
  • Mar 12, 2019: Acesion Pharma receives 5M DKK from Innovation Fund Denmark to support human Proof-of-concept study in atrial fibrillation (AF)
  • Feb 07, 2019: New patent issuances strengthen InCarda Therapeutics' Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies
  • Feb 07, 2019: Correvio announces presentation of Brinavess data at Belgian Society Of Cardiology 2019 Annual Congress
  • Nov 05, 2018: Acesion Pharma announces positive results for novel drug targeting atrial fibrillation
  • Oct 29, 2018: Correvio announces Brinavess eligibility for patent extension
  • Oct 23, 2018: Correvio announces intention to re-file Brinavess NDA in second quarter 2019
  • Sep 05, 2018: Correvio reports preliminary data collected from 2,000 Brinavess treatment episodes in EU post-authorization safety study
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Atrial Fibrillation, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2019
  • Atrial Fibrillation - Pipeline by Allergan Plc, H2 2019
  • Atrial Fibrillation - Pipeline by Allosteros Therapeutics Inc, H2 2019
  • Atrial Fibrillation - Pipeline by AnaBios Corp, H2 2019
  • Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Armaron Bio Pty Ltd, H2 2019
  • Atrial Fibrillation - Pipeline by Boston Pharmaceuticals Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Atrial Fibrillation - Pipeline by Correvio Pharma Corp, H2 2019
  • Atrial Fibrillation - Pipeline by Espero BioPharma Inc, H2 2019
  • Atrial Fibrillation - Pipeline by G3 Pharmaceuticals Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H2 2019
  • Atrial Fibrillation - Pipeline by HUYA Bioscience International LLC, H2 2019
  • Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Merck & Co Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2019
  • Atrial Fibrillation - Pipeline by Milestone Pharmaceuticals Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Nissan Chemical Corp, H2 2019
  • Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2019
  • Atrial Fibrillation - Pipeline by Rhythm Therapeutics Inc, H2 2019
  • Atrial Fibrillation - Pipeline by Rithim Biologics Inc, H2 2019
  • Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, H2 2019
  • Atrial Fibrillation - Pipeline by Toa Eiyo Ltd, H2 2019
  • Atrial Fibrillation - Pipeline by Verseon Corp, H2 2019
  • Atrial Fibrillation - Pipeline by Vivasc Therapeutics Inc, H2 2019
  • Atrial Fibrillation - Dormant Projects, H2 2019
  • Atrial Fibrillation - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Atrial Fibrillation - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Atrial Fibrillation - Discontinued Products, H2 2019
  • Atrial Fibrillation - Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development for Atrial Fibrillation, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top